Cargando…
Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
Autores principales: | Iizuka, Takashi, Iemitsu, Kotaro, Takihata, Masahiro, Takai, Masahiko, Nakajima, Shigeru, Minami, Nobuaki, Umezawa, Shinichi, Kanamori, Akira, Takeda, Hiroshi, Kawata, Takehiro, Ito, Shogo, Kikuchi, Taisuke, Amemiya, Hikaru, Kaneshiro, Mizuki, Mokubo, Atsuko, Takuma, Tetsuo, Machimura, Hideo, Tanaka, Keiji, Asakura, Taro, Kubota, Akira, Aoyagi, Sachio, Hoshino, Kazuhiko, Ishikawa, Masashi, Matsuzawa, Yoko, Obana, Mitsuo, Sasai, Nobuo, Kaneshige, Hideaki, Minagawa, Fuyuki, Saito, Tatsuya, Shinoda, Kazuaki, Miyakawa, Masaaki, Tanaka, Yasushi, Terauchi, Yasuo, Matsuba, Ikuro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737043/ https://www.ncbi.nlm.nih.gov/pubmed/26858805 http://dx.doi.org/10.14740/jocmr2417wc1 |
Ejemplares similares
-
Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
por: Iizuka, Takashi, et al.
Publicado: (2016) -
Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus
por: Kawata, Takehiro, et al.
Publicado: (2017) -
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study
por: Matsuba, Ikuro, et al.
Publicado: (2020) -
Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study
por: Iemitsu, Kotaro, et al.
Publicado: (2017) -
Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study
por: Iemitsu, Kotaro, et al.
Publicado: (2016)